Sign In
21 Sep 2009 07:00
ο»Ώ
21Β September 2009
Minster Pharmaceuticals plc
("Minster" or the "Company")
Minster Pharmaceuticals plcΒ (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that Robert Aubrey, an Executive Director,Β will step downΒ from executive responsibilitiesΒ with effect fromΒ 30 SeptemberΒ 2009Β to become aΒ Non-executive Director.
Mr Aubrey has served the CompanyΒ in an executive capacity forΒ a total of 8 years. He isΒ stepping down from executive responsibilities following the successful completion of the transfer ofΒ finance and internal control procedures to Karl Keegan, Chief Financial Officer, who was appointed in April 2009.
John Russell,Β Minster'sΒ Chairman,Β said:Β "Bob hasΒ made an impressiveΒ contributionΒ to MinsterΒ during hisΒ eightΒ years as an executive. We are particularlyΒ pleased that heΒ has agreedΒ toΒ continue to serve the Company asΒ aΒ Non-executive Director, through which we can continue to benefit from his wise counsel."
For further information:
Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623 John Russell, Chairman and Interim CEOΒ Karl Keegan, Chief Financial Officer Tel: +44 (0) 20 7936 9921 Buchanan Communications Tel: +44 (0) 20 7466 5000 Mark Court / Catherine BreenΒ Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200 Chris Collins / Richard Potts
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visitΒ www.minsterpharma.com
Follow the stocks
